Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology reported a significant year in 2022, recognizing $1.5 billion in collaboration revenue from sotrovimab. The company has a robust financial position with approximately $2.4 billion in cash and investments, allowing it to fund ongoing clinical trials in hepatitis B, hepatitis D, and influenza. Notable leadership transitions were announced, including the retirement of CEO George Scangos, effective April 3, 2023, and the appointment of Marianne De Backer as his successor. The company anticipates critical Phase 2 trial data and continues to progress in addressing COVID-19 and other infectious diseases.
Vir Biotechnology announced positive final draft guidance from the UK's NICE recommending the use of sotrovimab, a monoclonal antibody for COVID-19 treatment in adults at increased risk for severe disease.
This recommendation applies to patients who do not require supplemental oxygen and where alternatives like nirmatrelvir/ritonavir (Paxlovid) are unsuitable. Despite the positive guidance, no significant additional sales of sotrovimab in the UK are expected in 2023 due to existing inventory. Sotrovimab has received authorizations in over 40 countries but is not approved in the US.
Vir Biotechnology, a commercial-stage immunology company, announced it will provide a corporate update and report financial results for Q4 and full year 2022 on February 23, 2023. The financial results will be accessible via a press release after market close and can be found in the Investors section of their website.
Vir focuses on serious infectious diseases utilizing advanced immunologic technologies. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology has appointed Sung Lee as its new Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. He takes over from Howard Horn, who will remain in an advisory role during the transition. Lee brings over 20 years of experience in financial leadership, having held senior positions at companies like Gilead Sciences and most recently served as CFO at MorphoSys AG.
The company's CEO, George Scangos, expressed confidence in Lee’s ability to drive growth and strengthen financial performance. Horn, a key figure in Vir's early development, highlighted the company's strong financial foundation as he departs.
Vir Biotechnology announced an amendment to its collaboration agreement with GSK, allowing Vir to independently advance next-generation COVID-19 solutions and other respiratory therapies.
The companies will continue their partnership on sotrovimab and develop additional treatments for influenza. Sotrovimab, an investigational monoclonal antibody, is designed for optimal lung concentration but is not authorized in the US.
Vir retains rights to future developments from the collaboration while paying royalties to GSK. CEO George Scangos emphasized Vir's commitment to addressing urgent patient needs.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced the retirement of CEO George Scangos, effective April 3, 2023, transitioning to an advisory role until June 2, 2023. Marianne De Backer succeeds him, bringing over two decades of leadership experience, including roles at Bayer and Johnson & Johnson. Under Scangos, Vir developed life-saving therapies for Ebola and COVID-19, boasting a pipeline across five therapeutic areas and approximately $2.7 billion in cash. The Board expresses confidence in De Backer’s ability to drive future growth, leveraging her strategic expertise and operational successes.
Vir Biotechnology (Nasdaq: VIR) anticipates critical Phase 2 readouts in 2023 for its advanced programs targeting hepatitis B, hepatitis D, and influenza. CEO George Scangos will discuss the company's 2023 catalysts and long-term strategies at the upcoming J.P. Morgan Healthcare Conference on January 10. Vir maintains a strong balance sheet, enabling it to fund its robust portfolio and explore external opportunities. The company focuses on immunology to treat serious infectious diseases, leveraging four technology platforms for drug development.
Vir Biotechnology has successfully enrolled approximately 3,000 participants in the Phase 2 PENINSULA trial, assessing VIR-2482 for preventing influenza A illness. Initial results are anticipated in mid-2023. This trial is a landmark study as it explores a monoclonal antibody's role in flu prevention. The increasing severity of the flu season, highlighted by over 150,000 hospitalizations and 9,300 deaths in the U.S., underscores the urgent need for effective preventive measures. The trial's design focuses on efficacy, safety, and tolerability in healthy adults.
Vir Biotechnology has achieved a remarkable milestone by ranking first on the 2022 Deloitte Technology Fast 500, thanks to a staggering 125,138% revenue growth from fiscal years 2018 to 2021. This follows a 70th place ranking in 2021 for 2,383% growth. The CEO, George Scangos, attributes this success to the effective rollout of sotrovimab, a monoclonal antibody therapy for COVID-19, alongside a robust pipeline targeting serious infectious diseases. The company anticipates critical data readouts in hepatitis B, hepatitis D, and influenza A in 2023.
Vir Biotechnology announced promising results from ongoing trials of its HBV therapies, VIR-2218 and VIR-3434. Data revealed that 30.8% of participants achieved HBsAg seroclearance after 48 weeks of treatment combining VIR-2218 with pegylated interferon alpha. The trials showed substantial HBsAg reductions, with VIR-2218 demonstrating a mean decrease of -2.9 log10 IU/mL. No new safety concerns were reported. Additionally, findings from the Phase 2 MARCH trial indicated that the combination of VIR-2218 and VIR-3434 significantly reduced HBsAg levels.